Mumbai : Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company has launched SUTIB, which is a generic version of Sunitinib oral capsules to treat kidney cancer in India. The drug SUTIB is launched at a MRP that is approx. 96% lower than the MRP priced at Rs. 7000 (50 mg), Rs. 3600 (25 mg) and Rs. 1840 (12.5 mg) per month.
Sunitinib is also approved by the US Food and Drug Administration (US FDA).
In the past decade, advances in research and drug development have begun to shift the paradigm of this Kidney cancer. Sunitinib is an oral multi-kinase inhibitor (MKI), works by blocking several enzymes that promote cell growth. It is useful for the treatment of certain patients with gastrointestinal stromal tumors and advanced renal cell carcinoma. It is also approved for patients with certain type of Pancreatic Neuroendocrine Tumours.
“Oncology is an important focus area for Glenmark. We recognize that advanced kidney cancer is a complex disease and patients in India are faced with limited treatment options. Glenmark is committed to bringing targeted and effective medicines at an affordable cost to physicians and their patients.” said Mr. Alok Malik, Vice President & Business Head, Glenmark India Formulation
